TEMOZOLOMIDE
IEO 1411
Phase 2 small_molecule active
Quick answer
TEMOZOLOMIDE for Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions. is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Istituto Gentili S.r.l.
- Indication
- Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active